Literature DB >> 11326675

Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.

G M Oremek1, N Sapoutzis, W Kramer, R Bickeböller, D Jonas.   

Abstract

Pyruvate kinase is one of the glycolytic key enzymes. It exists in various isoforms which are expressed in different cell types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The concentration of Tu M2-PK in body fluids can be quantitatively determined by a commercially available enzyme-linked immunosorbent assay (ELISA)-kit. The Tu M2-PK concentration was measured in EDTA-plasma of 116 patients with renal carcinoma and 42 patients suffering from nephritis, by using this kit. The ranges of the Tu M2-PK-concentrations of the two groups did not overlap, indicating a highly significant discrimination of renal carcinoma and benign renal diseases. Furthermore, the Tu M2-PK concentration in EDTA-plasma correlated strongly with the Robson tumor stage of the 116 patients. The present results indicated that the Tu M2-PK might be the first tumor marker, which could be an excellent complementation of the diagnostic program for renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11326675

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

2.  Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.

Authors:  Won K Han; Anwar Alinani; Chin-Lee Wu; Dror Michaelson; Massimo Loda; Francis J McGovern; Ravi Thadhani; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2005-03-02       Impact factor: 10.121

3.  Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia.

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Abdulkader Albasri; Mohammad Ilyas; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2009-09-15       Impact factor: 4.430

4.  Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls.

Authors:  Bo Zhang; Jian-Ying Chen; Dao-Da Chen; Guo-Bin Wang; Ping Shen
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma.

Authors:  Corina Daniela Ene; Mircea Nicolae Penescu; Simona Roxana Georgescu; Mircea Tampa; Ilinca Nicolae
Journal:  Metabolites       Date:  2020-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.